Lilly’s Multiple Assumes Less Growth Than You Think

Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.

Eli Lilly (LLY) has returned 78.1% over the past year and trades at about 34.9 times the last twelve months of adjusted earnings, a number that makes buyers hesitate. The growth that consensus assumes is well below what the business is delivering now.

The Multiple Falls Without The Share Price Doing Anything

On the earnings analysts expect for 2027, today’s price is about 26.6 times earnings. None of that fall in the multiple comes from the stock moving; the earnings grow into a price already paid. Not all of the fall is earnings growth either. Although the trailing figure adds back stock-based compensation to approximate consensus, trailing and forward metrics are not defined identically—and for an acquisition-heavy company, that definitional mismatch can explain most of the multiple drop.

Consensus Is Already Forecasting A Sharp Slowdown

Consensus has earnings growing about 19.9% a year and revenue about 18.0% a year from the trailing twelve months through 2027, an eighteen-month horizon. Over those same trailing twelve months revenue grew 49.6%, and Mounjaro and Zepbound alone added $6.3 billion of year-over-year growth in the second quarter of 2026. The forward multiple does not extrapolate that boom; it assumes the boom ends.

U.S. price fell 3% in the second quarter of 2026, or 9% excluding a change to rebate and discount estimates, while Medicare GLP-1 Bridge coverage opened to 20 million eligible Americans in July and the oral drug Foundayo cleared the three major pharmacy benefit managers in June. U.S. price is already subtracting from the top line, though management expects volume growth to more than offset it.

The Ask Is On Margins, And Deal Charges Just Ate The Raise

Consensus also has earnings growing faster than revenue across its two forecast years, which means analysts are assuming margins keep expanding from an unusual base. For reference, the operating margin over the last twelve months was 49.7% against a three-year average of 39.0%. Margin strength of that kind is one of the properties the Trefis High Quality Portfolio favors in its holdings.

Management raised its 2026 revenue guidance to $85 billion to $87 billion against $79.67 billion of trailing-twelve-month revenue, and raised its margin guidance too. It cut the non-GAAP earnings guide anyway: a raise of $2.78 a share at the midpoint was more than taken back by $3.03 a share of second-quarter acquired IPR&D charges, because the pipeline it keeps buying is charged against the earnings the forward multiple rests on.

What The Slowdown Case Actually Pays A Holder

If consensus is right and the price never moves, 2027 only proves today’s price was not an overpayment. A gain needs the market to keep paying a premium multiple. Settle it at about 30.3 times those 2027 earnings, roughly halfway between today’s 33.9 times on 2026 earnings and that 26.6 times floor, and the stock is worth roughly 14% more than today, a scenario and not a target. The stock has also fallen as much as 47% peak to trough in past market shocks.

So you are not obviously overpaying, but you are paying for a forecast whose weak point is the earnings line, not the top line. Whether the guide can resume climbing is what to follow, and that decides what 26.6 times will mean.

What A Stock Is Worth And How Much To Own Are Different Questions

Valuation says what a stock might be worth, it says nothing about how much of your wealth should ride on it. A position that has grown large enough to matter is worth sizing deliberately rather than by accident. What a position that size would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.